Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00396110
Recruitment Status : Completed
First Posted : November 6, 2006
Last Update Posted : November 6, 2006
Information provided by:

Brief Summary:
In this study the effect of the switch to rosuvastatin from another statin (fluvastatin, pravastatin, simvastatin, atorvastatin) was evaluated in high-risk patients with and without evident CHD and LDL-C ≥ 3.2 mmol/l. This was done in a large observational study (TARGET) representing daily practice. Primary end points analysis was the percentage of patients reaching the target of LDL-C < 3.2 mmol/l. Secondary outcomes were the changes of LDL-C, HDL-C, TC, Triglycerides (TG) and TC/HDL-C-ratio from baseline.

Condition or disease
Hypercholesterolemia Coronary Heart Disease

Study Type : Observational
Enrollment : 3889 participants
Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)
Study Start Date : February 2003

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • High-risk patients with and without evident CHD who had LDL-C > 3.2 mmol/l and were treated at that moment with HMG-CoA-reductase inhibitor apart from rosuvastatin.
  • Patients were aged >18 years and <70 years (men) and < 75 years (women).

Exclusion Criteria:

  • Treatment with atorvastatin 40 or 80 mg or simvastatin 80 mg
  • Patients familiar with muscular pain, myopathy or liver function disorders (inclusive elevation of serum transaminases) and/or contra-indications for treatment with rosuvastatin

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00396110

Sponsors and Collaborators
Study Chair: Ingrid van Geel, MD AstraZeneca
Study Chair: Ingeborg Vosjan, MD AstraZeneca Identifier: NCT00396110     History of Changes
Other Study ID Numbers: 25V06
First Posted: November 6, 2006    Key Record Dates
Last Update Posted: November 6, 2006
Last Verified: February 2003

Keywords provided by AstraZeneca:
coronary heart disease
LDL-C goal

Additional relevant MeSH terms:
Heart Diseases
Coronary Disease
Coronary Artery Disease
Myocardial Ischemia
Cardiovascular Diseases
Lipid Metabolism Disorders
Metabolic Diseases
Vascular Diseases
Arterial Occlusive Diseases
Rosuvastatin Calcium
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors